Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

850
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
850
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

178
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
178
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.9K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

764
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
764

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing challenges in treating rare tumours: the strategy of China's National Cancer Center.

Nature reviews. Drug discovery·2026
Same author

Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020-2025.

Frontiers in public health·2026
Same author

Immunogenicity and safety of co-administered <i>Escherichia coli</i>-produced bivalent HPV-16/18 vaccine and hepatitis E vaccine.

Frontiers in immunology·2026
Same author

Population waning trajectories of vaccine-induced tetanus immunity in Zhejiang, China.

Frontiers in immunology·2026
Same author

Accuracy of Two Novel Self-Contained Darkroom Refractive Screeners Compared with Cycloplegic Retinoscopy and a Traditional Autorefractor in Schoolchildren.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Factors associated with serious adverse event following immunization: a real-world analysis of the vaccine adverse event reporting system 2025.

Frontiers in public health·2026

Related Experiment Video

Updated: Sep 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Insights into Support Systems for Orphan Drug Development: A Comparative Study.

Ye Leng1, Yu Tang2, Weijie Yu2

  • 1School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Therapeutic Innovation & Regulatory Science
|July 14, 2025
PubMed
Summary

Developing orphan drugs for rare diseases (RDs) requires harmonized support systems. This study proposes a framework and finds the US, EU, and China have basic conditions, with China needing improvements in incentives and infrastructure.

Keywords:
Clinical studyComparative studyOrphan drugRare diseaseSupport systems

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Related Experiment Videos

Last Updated: Sep 15, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Area of Science:

  • Health Policy and Orphan Drug Development
  • Rare Diseases Research and Regulatory Science

Background:

  • Orphan drug development addresses significant unmet medical needs for rare diseases (RDs).
  • A harmonized support system is crucial for advancing orphan drug development globally.

Purpose of the Study:

  • To propose a framework and dimensions of support systems influencing orphan drug development.
  • To assess the current state of orphan drug development conditions in the US, EU, and China.
  • To suggest action plans for strengthening global orphan drug development initiatives.

Main Methods:

  • Development of a support system framework encompassing legal, technical, motivational, and logistical factors.
  • Comparative analysis of orphan drug development conditions across the US, EU, and China based on the framework.
  • Formulation of strategic action plans for improving orphan drug development.

Main Results:

  • The US, EU, and China have established foundational conditions for orphan drug development.
  • China demonstrates deficiencies in economic incentives and fundamental infrastructure compared to the US and EU.
  • Specific areas for improvement in China include pricing, reimbursement, and real-world data (RWD) integration.

Conclusions:

  • A comprehensive framework is essential for evaluating and enhancing orphan drug development support systems.
  • Targeted improvements, particularly in China, are needed to meet the needs of rare disease patients.
  • The study provides a reference for national and global strategies to advance orphan drug development worldwide.